Sign in or create an account to add this stock to your watchlist.
About Asterias Biotherapeutics (NYSEAMERICAN:AST)
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:AST
CUSIPN/A
Phone+1-510-4563805
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-403.38%
Return on Equity-79.80%
Return on Assets-59.45%
Miscellaneous
EmployeesN/A
Outstanding Shares55,010,000
Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics (NYSEAMERICAN:AST) announced its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.03. The biotechnology company had revenue of $0.48 million for the quarter. Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%. View Asterias Biotherapeutics' Earnings History.
When is Asterias Biotherapeutics' next earnings date?
What price target have analysts set for AST?
2 brokers have issued 12-month price targets for Asterias Biotherapeutics' stock. Their forecasts range from $6.00 to $11.00. On average, they expect Asterias Biotherapeutics' share price to reach $8.50 in the next twelve months. View Analyst Ratings for Asterias Biotherapeutics.
Are investors shorting Asterias Biotherapeutics?
Asterias Biotherapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 3,906,010 shares, an increase of 5.7% from the April 30th total of 3,695,837 shares. Based on an average trading volume of 244,049 shares, the short-interest ratio is presently 16.0 days. Currently, 12.1% of the shares of the company are short sold.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix BioTherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Gr (MVF), Horizon Discovery (HZD), IMV (IMV), Bionomics (BNO), Fennec Pharmaceuticals (FRX), ImmunoVaccine (IMMVF), Arix Bioscience (ARIX) and Mereo BioPharma Group (MPH).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Dr. Katharine E. Spink, Consultant (Age 44)
- Dr. Jane S. Lebkowski Ph.D., Scientific Advisor (Age 62)
- Mr. Stephen L. Cartt, Advisor & Director (Age 55)
- Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)
- Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42)
Has Asterias Biotherapeutics been receiving favorable news coverage?
Press coverage about AST stock has trended somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a coverage optimism score of 0.17 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Asterias Biotherapeutics?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
One share of AST stock can currently be purchased for approximately $1.60.
How big of a company is Asterias Biotherapeutics?
Asterias Biotherapeutics has a market capitalization of $102.89 million.
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.
MarketBeat Community Rating for Asterias Biotherapeutics (AST)
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
Asterias Biotherapeutics (NYSEAMERICAN:AST) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trading and Institutional Ownership History
Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/25/2018 | Michael H Mulroy | Insider | Buy | 3,752 | $1.33 | $4,990.16 | |  |
| 3/26/2018 | Michael H Mulroy | Insider | Buy | 2,839 | $1.76 | $4,996.64 | | |
| 2/26/2018 | Michael H Mulroy | Insider | Buy | 2,255 | $2.22 | $5,006.10 | | |
| 1/25/2018 | Michael H Mulroy | Insider | Buy | 2,134 | $2.34 | $4,993.56 | | |
| 12/26/2017 | Michael H Mulroy | Insider | Buy | 2,247 | $2.22 | $4,988.34 | | |
| 11/27/2017 | Michael H Mulroy | Insider | Buy | 2,076 | $2.41 | $5,003.16 | | |
| 10/25/2017 | Michael H Mulroy | Insider | Buy | 1,939 | $2.55 | $4,944.45 | | |
| 9/25/2017 | Michael H. Mulroy | Insider | Buy | 1,537 | $3.25 | $4,995.25 | | |
| 1/9/2017 | Edward Wirth | Insider | Sell | 3,415 | $4.60 | $15,709.00 | 3,415 | |
| 1/9/2017 | Katharine E Spink | COO | Sell | 4,781 | $4.60 | $21,992.60 | 4,781 | |
| 10/6/2016 | Edward Wirth | Insider | Sell | 3,415 | $4.12 | $14,069.80 | | |
| 10/6/2016 | Katharine E. Spink | COO | Sell | 4,781 | $4.11 | $19,649.91 | | |
| 9/9/2016 | Edward Wirth | Insider | Sell | 14,760 | $3.52 | $51,955.20 | | |
| 9/9/2016 | Katharine E. Spink | COO | Sell | 19,336 | $3.52 | $68,062.72 | | |
| 6/30/2016 | Stephen Lahue Cartt | CEO | Buy | 10,000 | $2.40 | $24,000.00 | 260,000 | |
| 6/29/2016 | Richard T Lebuhn | Director | Buy | 5,000 | $2.38 | $11,900.00 | 25,000 | |
| 6/10/2016 | Stephen Lahue Cartt | CEO | Buy | 50,000 | $2.93 | $146,500.00 | 250,000 | |
| 6/9/2016 | Alfred D Kingsley | Director | Buy | 4,000 | $2.93 | $11,720.00 | 9,000 | |
| 5/13/2016 | Natale S Ricciardi | Director | Buy | 14,706 | $3.39 | $49,853.34 | 19,706 | |
| 9/16/2015 | Cary Pinkowski | Director | Sell | 409,000 | $0.0150 | $6,135.00 | | |
| 9/15/2015 | Edward Wirth | insider | Sell | 2,880 | $6.00 | $17,280.00 | | |
| 9/15/2015 | Katharine E. Spink | COO | Sell | 3,760 | $6.00 | $22,560.00 | | |
| 9/14/2015 | Cary Pinkowski | Director | Sell | 394,000 | $0.0150 | $5,910.00 | | |
| 6/25/2015 | Andrew Arno | Director | Buy | 5,000 | $4.32 | $21,600.00 | | |
| 2/9/2015 | Pedro Lichtinger | CEO | Buy | 128,205 | $3.90 | $499,999.50 | | |
| 10/1/2014 | Scarsdale Equities Llc | Major Shareholder | Buy | 60,000 | $5.93 | $355,800.00 | | |
(Data available from 1/1/2013 forward)
Asterias Biotherapeutics (NYSEAMERICAN AST) News Headlines
| Source: |
|
Asterias Biotherapeutics (NYSEAMERICAN:AST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Asterias Biotherapeutics (NYSEAMERICAN AST) Stock Chart for Thursday, May, 24, 2018
Loading chart…
